Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    14
ATC Name B/G Ingredients Dosage Form Price
C09DA03 CO-DIOVAN B Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 846,621 L.L
C09DA03 CO-ANGINET G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 544,256 L.L
C09DA03 CO-TABUVAN G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 544,256 L.L
C07AB07 CONCOR B Bisoprolol fumarate - 5mg 5mg Tablet, film coated 870,164 L.L
C09DA03 CO-DIOVAN B Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 901,718 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 20mg Tablet, film coated 1,251,117 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 40mg Tablet, film coated 1,358,625 L.L
C09DA04 CO APROVEL B Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
C09DA04 CO APROVEL B Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
C09DA04 CONVERIUM PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
L01EX07 CABOMETYX B Cabozantinib - 20mg 20mg Tablet, film coated 440,893,501 L.L
L01EX07 CABOMETYX B Cabozantinib - 40mg 40mg Tablet, film coated 440,893,501 L.L
C07AB07 CONCOR B Bisoprolol fumarate - 10mg 10mg Tablet, film coated 1,176,665 L.L
L01EX07 CABOMETYX B Cabozantinib - 60mg 60mg Tablet, film coated 440,893,501 L.L
N06AB10 CIPRALEX B Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 1,548,107 L.L
C09DA04 CO APROVEL B Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
N06AB10 CITOLES G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 511,940 L.L
C09DA04 CO APROVEL B Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 1,410,395 L.L
C09DA04 CONVERIUM PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C07AB07 CONCOR COR B Bisoprolol fumarate - 2.5mg 2.5mg Tablet, film coated 488,906 L.L
N06AB10 CIPRALEX B Escitalopram (oxalate) - 15mg 15mg Tablet, film coated 2,378,601 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 15mg 15mg Tablet, film coated 2,166,786 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 20mg 20mg Tablet, film coated 2,559,700 L.L
N04BA03 COMBIPAR G Levodopa - 100mg, Carbidopa - 25mg, Entacapone - 200mg Tablet, film coated 1,249,926 L.L
N04BA03 COMBIPAR G Levodopa - 150mg, Carbidopa - 37.5mg, Entacapone - 200mg Tablet, film coated 1,324,682 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
N04BA03 COMBIPAR G Levodopa - 50mg, Carbidopa - 12.5mg, Entacapone - 200mg Tablet, film coated 1,103,403 L.L
M01AH05 CONSORT G Etoricoxib - 60mg 60mg Tablet, film coated 338,648 L.L
M01AH05 COXIFLAM G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
    ...
    14
Sitemap
© Copyrights reserved to Ministry of Public Health 2025